Abstract
Chemoradiotherapy can induce immunogenic cell death, triggering danger signals such as high-mobility group box 1 protein, and resulting in T-cell immunity. This concept can potentially be harnessed for clinical therapy to enhance tumor-specific immunity. There is however limited information to translate this theory directly in a clinical setting. In this review, we will discuss and summarize molecular and cellular mechanisms underlying immunogenic tumor cell death induced by chemoradiotherapy, with emphasis on a clinical translation.
MeSH terms
-
Animals
-
Antigens, Neoplasm / immunology
-
Calreticulin / metabolism
-
Chemoradiotherapy
-
Cytotoxicity, Immunologic
-
Dendritic Cells / immunology
-
Dendritic Cells / metabolism
-
HMGB1 Protein / metabolism
-
Humans
-
Neoplasms / immunology
-
Neoplasms / metabolism
-
Neoplasms / therapy*
-
T-Lymphocytes, Cytotoxic / immunology
-
T-Lymphocytes, Cytotoxic / metabolism
-
T-Lymphocytes, Cytotoxic / radiation effects
-
Toll-Like Receptor 4 / metabolism
-
Translational Research, Biomedical
Substances
-
Antigens, Neoplasm
-
Calreticulin
-
HMGB1 Protein
-
HMGB1 protein, human
-
TLR4 protein, human
-
Toll-Like Receptor 4